SEARCH RESULTS

176323 RESULTS

At AD/PD Conference, New BACE Inhibitor Struts Its Stuff

CONFERENCE COVERAGE 2015-04-01 Conference Coverage Striving to be noticed in the hoopla over Biogen’s Phase 1 aducanumab data, other investigational therapies presented clinical data at the 12th International Conference on Alzheimer’s and Parkinson’s diseases, held March 18 to 22 in ...

PRX002

THERAPEUTICS Prothena Corporation plc Immunotherapy (passive) Unknown PRX002 is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Genetic and pathological evidence suggest that this protein plays a central role in the pathogenesis of ...

Antibody Against α-Synuclein Looks Safe In Early Trials

CONFERENCE COVERAGE 2015-03-31 Conference Coverage People with Parkinson’s disease have treatment options, but none directly tackle the underlying pathology of misfolded and aggregated α-synuclein. That may be poised to change, with numerous approaches targeting the protein now in the ...

Professor/Associate Professor in Pharmacology

JOB 2015-03-31 Employer University of Oslo Principal Investigator Lars Nilsson Contact Please submit your application electronically at http://uio.easycruit.com/. For questions on the positions, please contact Professor Lars Nilsson, lars.nilsson@medisin.uio.no ...

International Conference on Alzheimer's & Parkinson’s Diseases 2015

CONFERENCE COVERAGE SERIES Biogen Antibody Buoyed by Phase 1 Data and Hungry Investors Antibody Against α-Synuclein Looks Safe In Early Trials At AD/PD Conference, New BACE Inhibitor Struts Its Stuff The 12th AD/PD conference drew some 3,100 people from across the world to the ...

Ueda Naoya


Center for Development of Advanced Medicine for Dementia
Obu

Current Filters

No filters selected

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE